List view / Grid view
Filter the results
Protein Or not? Advanced high throughput aggregate analysis with The Aura™ - Find the problem before it happens particle analysis reimagined.
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.
Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
26 June 2020 | By Tecan
This webinar will describe recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
A study has revealed 68 protein-coding genes associated with risk of severe COVID-19, nine of which are targeted by drugs currently in clinical trials.
Over the past year, BellBrook Labs has leveraged its Transcreener HTS Assay technology to build enabling products and services focusing on innate immunity targets.
By administering a one-time PTB antisense oligonucleotide therapy to mice, researchers observed an increase in neurons and elimination of Parkinson's from the models.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.
An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.